Background In persons with type 1 diabetes and high glycated hemoglobin levels, the benefits
of intermittently scanned continuous glucose monitoring with optional alarms for high and …

The COVID-19 pandemic has had major health and economic effects across the world. At
the time of writing (May, 2021), there have been more than 127 000 COVID-related deaths in …

Objective To compare rates of performing National Institute for Health and Care Excellence-recommended
health checks and prescribing in people with type 2 diabetes (T2D), before …

Background Evidence for management of asthma comes from closely monitored efficacy
trials done in highly selected patient groups. There is a need for randomised trials that are …

The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and
Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of …

Purpose Some classes of glucose-lowering medications, including sodium-glucose co-transporter
2 inhibitors (SGLT2is) and glucagon-like peptide 1-receptor agonists (GLP1-RAs) …

Background Despite advances in the treatment of heart failure (HF) with reduced ejection
fraction, people with HF continue to have a high risk of mortality and hospitalisation. Patients …

Type 2 diabetes is one of the fastest-growing health emergencies of the twenty-first century,
in part due to its association with cardiovascular and renal disease. Successful …

In this review, we identify some general and diabetes-specific risk factors that are associated
with an increased risk of developing heart failure in people with T2D.

Introduction As the therapeutic options in the management of type 2 diabetes increase, there
is an increase confusion among health care professionals, thus leading to the phenomenon …